Avanafil - a further step to tailoring patient needs and expectations (Q38846047)

6 September 2017

1 reference

title

Avanafil - a further step to tailoring patient needs and expectations (English)

1 reference

6 September 2017

Francesco Montorsi

1 reference

6 September 2017

Luca Boeri

1 reference

6 September 2017

Paolo Capogrosso

1 reference

6 September 2017

Eugenio Ventimiglia

1 reference

6 September 2017

Alessandro Serino

1 reference

6 September 2017

Giovanni La Croce

1 reference

6 September 2017

Andrea Russo

1 reference

6 September 2017

Rocco Damiano

1 reference

6 September 2017

Andrea Salonia

1 reference

6 September 2017

language of work or name

English

0 references

publication date

27 May 2016

1 reference

Expert Review of Clinical Pharmacology

6 September 2017

published in

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

page(s)

1171-1181

1 reference

Incidence and Prevalence of Sexual Dysfunction in Women and Men: A Consensus Statement from the Fourth International Consultation on Sexual Medicine 2015.

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

One patient out of four with newly diagnosed erectile dysfunction is a young man--worrisome picture from the everyday clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

SOP conservative (medical and mechanical) treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Endocrinologic Control of Men's Sexual Desire and Arousal/Erection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Sildenafil in erectile dysfunction: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Vardenafil orodispersible tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Treating erectile dysfunction when PDE5 inhibitors fail

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

PDE5 inhibitors: considerations for preference and long-term adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Erectile dysfunction in heart failure patients: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

British Society for Sexual Medicine guidelines on the management of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Health outcomes variables important to patients in the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Duration of erection: does it really matter? A randomized, double-blind clinical trial to assess the impact of vardenafil ODT on duration of erection and its correlation with patients' and partners' sexual quality of life and duration of intercourse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Avanafil: a review of its use in patients with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Anatomy, physiology, and pathophysiology of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

The role of nitric oxide in erectile dysfunction: implications for medical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Are Phosphodiesterase Type 5 Inhibitors Associated with Vision-Threatening Adverse Events? A Critical Analysis and Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Phosphodiesterase inhibitors in clinical urology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

Results from an online survey investigating ED patients' insights and treatment expectations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2016.1195261

10.1080/17512433.2016.1195261

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference